Related Experiment Video
Updated: Aug 7, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
A modern plan for treating hypertension
1Cardiovascular Center, New York Hospital-Cornell Medical Center, NY 10021.
Insights
Essential hypertension is not a single disease but has two main causes: renin-mediated and sodium-volume-mediated vasoconstriction. Understanding these mechanisms allows for targeted drug therapies, improving treatment for hypertension.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Essential hypertension presents as a complex spectrum of pathophysiologic disturbances.
- Distinguishing between different vasoconstrictor mechanisms is crucial for effective treatment.
Purpose of the Study:
- To characterize the two primary vasoconstrictor mechanisms in essential hypertension: renin-mediated and sodium-volume-mediated.
- To establish a rational basis for antihypertensive drug therapy and identify curable conditions.
Main Methods:
- Identification and characterization of renin-mediated and sodium-volume-mediated vasoconstriction.
- Classification of antihypertensive drugs based on their mechanism of action.
Main Results:
- Two distinct vasoconstrictor mechanisms identified: one renin-mediated, the other sodium-volume mediated.
- Five major drug classes identified for monotherapy: converting enzyme inhibitors, beta-blockers, diuretics, calcium-channel antagonists, and alpha-blockers.
- Therapeutic strategies enable screening for curable renovascular disease and primary aldosteronism.
Conclusions:
- Understanding the underlying mechanisms of essential hypertension allows for more targeted and rational drug selection.
- Long-term monotherapy for essential hypertension is achievable with appropriate drug choices.
- The goal of therapy is to minimize drug количество, dosage, and frequency for lifelong management.
Abstract:
Essential hypertension is a heterogeneous spectrum of pathophysiologic disturbances, not a single entity. Identification and characterization of two different vasoconstrictor mechanisms--one renin-mediated, the other sodium-volume mediated--has made it possible not only to apply antihypertensive drug therapy on a more rational basis but to screen out a significant number of cases of curable (high-renin) renovascular disease as well as many cases of curable (low-renin) primary aldosteronism. An array of five major drug types makes long-term monotherapy for essential hypertension an achievable goal. Converting enzyme inhibitors and beta-blockers counteract the renin-mediated vasoconstriction; diuretics, calcium-channel antagonists, and alpha-blockers oppose the low-renin sodium-volume-mediated form of vasoconstriction. This information brings us closer to the primary goal of modern therapy: to give each patient the fewest drugs in the smallest amounts and with the least frequency possible for the often lifetime commitment that antihypertensive therapy involves.
More Related Videos
Related Concept Videos
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antihypertensive Drugs: Vasodilators
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension I: Introduction
Hypertension IV: Drug Therapy and Lifestyle Modifications

